Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
TRVIthis companyTrevi Therapeutics, Inc.	$15.14	-43.17×	9.91×	0×	-42.14×	-99.2%	0.0%	0.0%	0.0%	-23.3%	-26.8%	-2.3%	0×	0.43×	0×	19.66×	0.0%	1	128.4	2	C
ACADAcadia Pharmaceuticals Inc.	$21.38	11.51×	3.69×	4.22×	29.19×	-252.2%	91.7%	9.8%	36.5%	31.9%	8.1%	2.3%	0.04×	-0.83×	0×	3.83×	0.0%	4	4.87	4	A-
LQDALiquidia Corporation	$47.62	-43.11×	66.33×	18.75×	-68.84×	-288.6%	91.6%	-32.5%	-43.5%	-154.0%	-20.5%	-1.3%	4.42×	-0.17×	-2.13×	1.4×	0.0%	6	8.09	3	B-
LXRXLexicon Pharmaceuticals, Inc.	$1.87	-8.21×	3.88×	8.38×	-10.76×	-701.5%	99.4%	-98.2%	-101.1%	-46.8%	-28.7%	-16.3%	0.58×	-0.67×	-5.87×	4.88×	0.0%	2	-6.05	1	D+
RAPPRapport Therapeutics, Inc. Common Stock	$24.84	-10.61×	2.94×	0×	-11.16×	-96.8%	0.0%	0.0%	0.0%	-23.0%	-25.2%	-6.2%	0.02×	0.33×	0×	26.17×	0.0%	2	19.18	2	C
TENXTenax Therapeutics, Inc.	$1.82	-9.1×	4.92×	0×	-7.23×	30.4%	0.0%	0.0%	0.0%	-54.2%	-58.1%	-7.5%	0×	1.85×	0×	14.56×	0.0%	1	-1.73	1	C-
Peer median	—	-9.1×	3.88×	4.22×	-10.76×	-252.2%	91.6%	0.0%	0.0%	-46.8%	-25.2%	-6.2%	0.04×	-0.17×	0×	4.88×	0.0%	2	4.87	2	—